About Esperion Therapeutics (NASDAQ:ESPR)
Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ESPR
CUSIPN/A
Phone734-887-3903
Debt
Debt-to-Equity RatioN/A
Current Ratio6.15%
Quick Ratio6.15%
Price-To-Earnings
Trailing P/E Ratio-10.02
Forward P/E Ratio-12.47
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$9.34 per share
Price / Book7.49
Profitability
EPS (Most Recent Fiscal Year)($6.98)
Net Income$-166,980,000.00
Net MarginsN/A
Return on Equity-76.84%
Return on Assets-67.42%
Miscellaneous
Employees57
Outstanding Shares26,750,000
Esperion Therapeutics (NASDAQ:ESPR) Frequently Asked Questions
What is Esperion Therapeutics' stock symbol?
Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."
How were Esperion Therapeutics' earnings last quarter?
Esperion Therapeutics (NASDAQ:ESPR) announced its earnings results on Tuesday, February, 20th. The biopharmaceutical company reported ($1.44) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($1.80) by $0.36. During the same quarter in the prior year, the firm earned ($1.29) EPS. View Esperion Therapeutics' Earnings History.
When is Esperion Therapeutics' next earnings date?
What price target have analysts set for ESPR?
13 equities research analysts have issued 1 year price objectives for Esperion Therapeutics' stock. Their predictions range from $64.00 to $153.00. On average, they expect Esperion Therapeutics' share price to reach $96.3077 in the next year. View Analyst Ratings for Esperion Therapeutics.
What are Wall Street analysts saying about Esperion Therapeutics stock?
Here are some recent quotes from research analysts about Esperion Therapeutics stock:
- 1. Chardan Capital analysts commented, "We see numerous reasons for our new positive bias, including: A path forward for both BA and a BA+ezetimibe (BA+eze) fixed dose combo (FDC) has been confirmed by the FDA. A definition of statin intolerance has also been agreed on by the FDA. KOLs (e.g. Dr. Nissen) support the need for therapies for patients who are (or believe themselves to be) statin intolerant and refuse statins. CANTOS suggests BA’s high-sensitivity C-reactive protein (hsCRP) lowering effect is highly relevant for CV event reduction and outcomes. Newly-disclosed integrated phase II results suggest sound BA safety. A larger market opportunity results from a pivotal BA phase III design that includes patients “on any statin dose.” Limited use of PCSK9 inhibitors, due to pricing, opens an opportunity. Merck’s (unrated) decision not to file anacetrapib for approval further confirms oral CETP inhibitors as uninteresting assets or competitors." (12/5/2017)
- 2. According to Zacks Investment Research, "Esperion Therapeutics, Inc. is a biopharmaceutical company. It focused on the research, development and commercialization of therapies for low-density lipoprotein cholesterol and other cardiometabolic risk factors. Esperion Therapeutics, Inc. is based in Plymouth, Michigan. " (8/23/2017)
Who are some of Esperion Therapeutics' key competitors?
Some companies that are related to Esperion Therapeutics include Alkermes (ALKS), SAGE Therapeutics (SAGE), Ionis Pharmaceuticals (IONS), Valeant Pharmaceuticals International (VRX), Catalent (CTLT), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Agios Pharmaceuticals (AGIO), Galápagos (GLPG), United Therapeutics (UTHR), Hutchison China MediTech (HCM), Taro Pharmaceutical Industries (TARO), Loxo Oncology (LOXO), FibroGen (FGEN) and GW Pharmaceuticals (GWPH).
Who are Esperion Therapeutics' key executives?
Esperion Therapeutics' management team includes the folowing people:
- Mr. Timothy M. Mayleben, CEO, Pres & Director (Age 57)
- Dr. Narendra D. Lalwani Ph.D., FAHA, DABT, MBA, Chief Operating Officer and Exec. VP of R&D (Age 65)
- Dr. Mary P. McGowan M.D., Chief Medical Officer (Age 58)
- Mr. Richard B. Bartram, CFO, Principal Accounting Officer & Corp. Sec.
- Ms. Marianne Andreach, Sr. VP of Product Planning
Has Esperion Therapeutics been receiving favorable news coverage?
Headlines about ESPR stock have trended positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Esperion Therapeutics earned a news impact score of 0.35 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 48.19 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
Who are Esperion Therapeutics' major shareholders?
Esperion Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include
DOMAIN PARTERS VII L P
(4.20%). Company insiders that own Esperion Therapeutics stock include Dov A Md Goldstein, Gilbert S Omenn, Mark E Mcgovern, Narendra D Lalwani, Nicole Vitullo, Roger S Newton and Timothy M Mayleben. View Institutional Ownership Trends for Esperion Therapeutics.
How do I buy shares of Esperion Therapeutics?
Shares of ESPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Esperion Therapeutics' stock price today?
One share of ESPR stock can currently be purchased for approximately $69.95.
How big of a company is Esperion Therapeutics?
Esperion Therapeutics has a market capitalization of $1.97 billion. The biopharmaceutical company earns $-166,980,000.00 in net income (profit) each year or ($6.98) on an earnings per share basis. Esperion Therapeutics employs 57 workers across the globe.
How can I contact Esperion Therapeutics?
Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The biopharmaceutical company can be reached via phone at 734-887-3903 or via email at [email protected]
MarketBeat Community Rating for Esperion Therapeutics (ESPR)
MarketBeat's community ratings are surveys of what our community members think about Esperion Therapeutics and other stocks. Vote "Outperform" if you believe ESPR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ESPR will underperform the S&P 500 over the long term. You may vote once every thirty days.
Esperion Therapeutics (NASDAQ:ESPR) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
13 Wall Street analysts have issued ratings and price targets for Esperion Therapeutics in the last 12 months. Their average twelve-month price target is $96.3077, suggesting that the stock has a possible upside of 37.68%. The high price target for ESPR is $153.00 and the low price target for ESPR is $64.00. There are currently 4 hold ratings, 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.77 | 2.77 | 2.77 | 2.69 |
| Ratings Breakdown: | 0 Sell Rating(s)
4 Hold Rating(s)
8 Buy Rating(s)
1 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
8 Buy Rating(s)
1 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
8 Buy Rating(s)
1 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $96.3077 | $90.6154 | $77.2308 | $58.9167 |
| Price Target Upside: | 37.68% upside | 20.40% upside | 0.04% upside | 9.02% upside |
Esperion Therapeutics (NASDAQ:ESPR) Consensus Price Target History
Esperion Therapeutics (NASDAQ:ESPR) Analyst Ratings History
Show:
(Data available from 4/25/2016 forward)
Esperion Therapeutics (NASDAQ:ESPR) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Esperion Therapeutics (NASDAQ ESPR) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 14.50%
Institutional Ownership Percentage: 89.93%
Esperion Therapeutics (NASDAQ ESPR) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/29/2018 | Roger S Newton | Director | Sell | 25,000 | $72.37 | $1,809,250.00 | 639,682 |  |
| 1/25/2018 | Nicole Vitullo | Director | Sell | 11,674 | $71.79 | $838,076.46 | 3,177 | |
| 12/6/2017 | Nicole Vitullo | Director | Sell | 9,326 | $53.85 | $502,205.10 | 2,472 | |
| 3/22/2017 | Dov A Md Goldstein | Director | Sell | 800,000 | $41.66 | $33,328,000.00 | | |
| 3/21/2017 | Gilbert S Omenn | Director | Buy | 1,000 | $42.26 | $42,260.00 | 10,000 | |
| 11/1/2016 | Narendra D Lalwani | COO | Buy | 5,000 | $9.93 | $49,650.00 | 5,000 | |
| 7/6/2016 | Mark E Mcgovern | Director | Buy | 5,000 | $10.00 | $50,000.00 | 600 | |
| 5/4/2016 | Timothy M Mayleben | CEO | Buy | 7,000 | $14.85 | $103,950.00 | 41,614 | |
| 3/1/2016 | Gilbert S Omenn | Director | Buy | 5,000 | $15.28 | $76,400.00 | 10,000 | |
| 1/27/2016 | Timothy M Mayleben | CEO | Buy | 3,600 | $15.88 | $57,168.00 | 34,614 | |
| 1/15/2016 | Timothy M Mayleben | CEO | Buy | 7,200 | $14.08 | $101,376.00 | 31,014 | |
| 4/24/2015 | Dov A Md Goldstein | Director | Sell | 217,469 | $108.22 | $23,534,495.18 | | |
| 11/18/2014 | Patrick G Enright | Director | Sell | 487,130 | $32.78 | $15,968,121.40 | | |
| 10/21/2014 | Parters Vii L P Domain | Major Shareholder | Buy | 500,000 | $20.00 | $10,000,000.00 | | |
| 10/7/2014 | Longitude Capital Partners, Ll | Major Shareholder | Sell | 11,927 | $30.04 | $358,287.08 | | |
| 7/1/2013 | Brian H Dovey | Major Shareholder | Buy | 285,714 | $14.00 | $3,999,996.00 | | |
| 7/1/2013 | Daniel Janney | Director | Buy | 235,714 | $14.00 | $3,299,996.00 | | |
| 7/1/2013 | Roger S Newton | Chairman | Buy | 42,346 | $14.00 | $592,844.00 | | |
| 7/1/2013 | Timothy M Mayleben | CEO | Buy | 5,000 | $14.00 | $70,000.00 | | |
(Data available from 1/1/2013 forward)
Esperion Therapeutics (NASDAQ ESPR) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Esperion Therapeutics' (ESPR) "Buy" Rating Reiterated at UBS
www.americanbankingnews.com - April 20 at 3:36 PM |
 | Esperion Therapeutics (ESPR) PT Raised to $121 at Northland to Reflect High Confidence in P3 Outcomes
www.streetinsider.com - April 20 at 8:51 AM |
| Northland Securities Boosts Esperion Therapeutics (ESPR) Price Target to $121.00
www.americanbankingnews.com - April 19 at 3:36 PM |
| Esperion Therapeutics (ESPR) Expected to Announce Earnings of -$1.56 Per Share
www.americanbankingnews.com - April 15 at 1:19 AM |
| Esperion Therapeutics (ESPR) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 12 at 3:31 PM |
| Esperion Therapeutics (ESPR) Given a $64.00 Price Target at Deutsche Bank
www.americanbankingnews.com - April 11 at 7:18 PM |
| Esperion Therapeutics (ESPR) Receives "Buy" Rating from Stifel Nicolaus
www.americanbankingnews.com - April 11 at 5:35 PM |
| Esperion Therapeutics (ESPR) Earns Buy Rating from Stifel Nicolaus
www.americanbankingnews.com - April 8 at 12:40 AM |
| Esperion Therapeutics' (ESPR) "Buy" Rating Reiterated at Northland Securities
www.americanbankingnews.com - April 8 at 12:40 AM |
| Esperion Therapeutics (ESPR) Rating Increased to Buy at ValuEngine
www.americanbankingnews.com - April 3 at 4:16 PM |
| Insider Selling: Esperion Therapeutics (ESPR) Director Sells 25,000 Shares of Stock
www.americanbankingnews.com - March 29 at 10:10 PM |
 | Pre-Market Technical Scan on Biotech Equities -- Eleven Biotherapeutics, Endocyte, Esperion Therapeutics, and Exelixis
www.prnewswire.com - March 29 at 8:55 AM |
 | Esperion Therapeutics (ESPR) Study 1002-039 Phase 2 Top-Line Results - Slideshow
seekingalpha.com - March 28 at 5:00 PM |
| Esperion Therapeutics (ESPR) PT Set at $105.00 by Stifel Nicolaus
www.americanbankingnews.com - March 28 at 3:48 PM |
| Esperion Nets Another Positive Late-Stage Study Under Its Belt
seekingalpha.com - March 28 at 8:57 AM |
 | Results Renew Optimism for Esperion Therapeutics
finance.yahoo.com - March 28 at 8:57 AM |
| Esperion Therapeutics (ESPR) PT Set at $88.00 by UBS
www.americanbankingnews.com - March 27 at 6:48 PM |
| Esperion Therapeutics (ESPR) PT Raised to $100.00
www.americanbankingnews.com - March 27 at 5:10 PM |
 | Esperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor ...
globenewswire.com - March 27 at 4:55 PM |
 | Biohaven's IPO Roadshow Fantasy Meets Grimmer Reality
www.bloomberg.com - March 27 at 4:55 PM |
 | Notable Tuesday Option Activity: GPRO, ESPR, INTC
www.nasdaq.com - March 27 at 4:55 PM |
| Esperion Therapeutics (ESPR) PT Raised to $100 at Chardan Capital Markets
www.streetinsider.com - March 27 at 4:55 PM |
| Will Esperion Therapeutics Inc’s (NASDAQ:ESPR) Earnings Grow In The Years Ahead?
finance.yahoo.com - March 27 at 4:55 PM |
| Esperion Therapeutics (ESPR) Stock Rating Lowered by Citigroup
www.americanbankingnews.com - March 27 at 11:01 AM |
| Esperion's drug clears study as add-on cholesterol treatment
finance.yahoo.com - March 27 at 9:01 AM |
| Esperion Therapeutics (ESPR) Lifted to Hold at ValuEngine
www.americanbankingnews.com - March 25 at 6:25 PM |
| BidaskClub Downgrades Esperion Therapeutics (ESPR) to Hold
www.americanbankingnews.com - March 24 at 10:48 AM |
| Esperion Therapeutics Inc (ESPR) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 18 at 3:27 PM |
| -$1.45 Earnings Per Share Expected for Esperion Therapeutics Inc (ESPR) This Quarter
www.americanbankingnews.com - March 11 at 8:35 PM |
| Head-To-Head Comparison: AEterna Zentaris (AEZS) vs. Esperion Therapeutics (ESPR)
www.americanbankingnews.com - March 11 at 6:19 PM |
| Esperion Therapeutics (ESPR) Downgraded to Buy at BidaskClub
www.americanbankingnews.com - March 10 at 6:34 PM |
| Esperion Therapeutics (ESPR) PT Raised to $153.00 at JMP Securities
www.americanbankingnews.com - March 8 at 10:31 PM |
 | UPDATE: Esperion reports positive results in late-stage trial of heart disease treatment , shares jump 4% - MarketWatch
www.marketwatch.com - March 8 at 8:52 AM |
| After A Two-Decade Quest, Will Esperion's Heart Drug Find A Market?
finance.yahoo.com - March 7 at 6:01 PM |
| Has Esperion Therapeutics Inc (NASDAQ:ESPR) Got Enough Cash To Cover Its Short-Term Obligations?
finance.yahoo.com - March 7 at 6:01 PM |
| Esperion to Participate in Fireside Chat at March 2018 Investor Conferences
finance.yahoo.com - March 7 at 6:01 PM |
| Esperion Tanked Despite Strong Cholesterol Drug Trial — Here's Why
finance.yahoo.com - March 7 at 6:01 PM |
| Esperion Releases Top Line Results For First Pivotal Phase 3 Study
finance.yahoo.com - March 7 at 8:50 AM |
| Esperion Announces Positive Top-Line Results from First Pivotal Phase 3 Study of Bempedoic Acid
finance.yahoo.com - March 7 at 8:50 AM |
| UPDATE: Esperion reports positive results in late-stage trial of heart disease treatment , shares jump 4%
finance.yahoo.com - March 7 at 8:50 AM |
| 23,333 Shares in Esperion Therapeutics Inc (ESPR) Purchased by Sectoral Asset Management Inc
www.americanbankingnews.com - March 6 at 2:11 PM |
 | Is the Options Market Predicting a Spike in Esperion (ESPR) Stock?
www.zacks.com - March 2 at 8:41 AM |
| Ascend Capital LLC Purchases Shares of 67,241 Esperion Therapeutics Inc (ESPR)
www.americanbankingnews.com - March 2 at 4:33 AM |
| Esperion Therapeutics Inc (ESPR) Stake Lessened by EAM Investors LLC
www.americanbankingnews.com - February 27 at 3:00 PM |
| American Century Companies Inc. Invests $1.60 Million in Esperion Therapeutics Inc (ESPR) Stock
www.americanbankingnews.com - February 27 at 4:06 AM |
| Ontario Teachers Pension Plan Board Invests $1.64 Million in Esperion Therapeutics Inc (ESPR) Stock
www.americanbankingnews.com - February 26 at 12:28 PM |
| Esperion Targets $10 a Day for Heart Pill to Undercut Rivals
finance.yahoo.com - February 23 at 5:33 PM |
| Q1 2018 EPS Estimates for Esperion Therapeutics Inc (ESPR) Lifted by Analyst
www.americanbankingnews.com - February 23 at 9:59 AM |
| Stock Traders Buy Large Volume of Esperion Therapeutics Put Options (ESPR)
www.americanbankingnews.com - February 23 at 8:26 AM |
| Analysts Expect Esperion Therapeutics Inc (ESPR) to Post -$1.95 EPS
www.americanbankingnews.com - February 23 at 3:14 AM |
Esperion Therapeutics (NASDAQ:ESPR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Esperion Therapeutics (NASDAQ:ESPR) Income Statement, Balance Sheet and Cash Flow Statement
Esperion Therapeutics (NASDAQ ESPR) Stock Chart for Wednesday, April, 25, 2018
Loading chart…
